# Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

> **NCT04911816** · PHASE1,PHASE2 · RECRUITING · sponsor: **West Virginia University** · enrollment: 40 (estimated)

## Conditions studied

- Adenocarcinoma of the Pancreas

## Interventions

- **DRUG:** Hydroxychloroquine sulfate

## Key facts

- **NCT ID:** NCT04911816
- **Lead sponsor:** West Virginia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-16
- **Primary completion:** 2027-06
- **Final completion:** 2030-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04911816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04911816, "Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04911816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*